News
AIM
0.1900
-0.58%
-0.0011
AIM ImmunoTech Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
Barchart · 5d ago
AIM Immunotech receives non-compliance notice from NYSE American
Seeking Alpha · 5d ago
AIM ImmunoTech receives noncompliance notification from NYSE
TipRanks · 5d ago
Weekly Report: what happened at AIM last week (1209-1213)?
Weekly Report · 6d ago
Aim ImmunoTech Urges Shareholders To Vote On The White Universal Proxy Card "For" All 4 Incumbent Board Members; Believes Future Of The Co And That The Current Board Is Best Positioned To Continue Clinical Trial Momentum, Commercialize Ampligen And Deliver Long-Term Value For Shareholders
Benzinga · 12/12 20:03
AIM ImmunoTech Inc. Granted Patent for Ampligen® in Treatment of Post-COVID Fatigue
Barchart · 12/12 18:28
AIM ImmunoTech expands patent portfolio with new Netherlands patent
TipRanks · 12/12 14:15
AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members
Barchart · 12/12 14:00
Kellner Group says former AIM ImmunoTech executive supports nominees
TipRanks · 12/12 13:20
Kellner Group urges AIM ImmunoTech stockholders to vote for its nominees
TipRanks · 12/11 12:41
AIM ImmunoTech says Glass Lewis recommends shareholders vote for nominees
TipRanks · 12/10 15:25
Kellner Group announces former CEO to join SAB if nominees elected
TipRanks · 12/10 12:40
AIM ImmunoTech Price Target Cut to $4.50/Share From $5.00 by Ascendiant Capital
Dow Jones · 12/10 09:40
Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $4.5
Benzinga · 12/10 09:31
Weekly Report: what happened at AIM last week (1202-1206)?
Weekly Report · 12/09 10:24
AIM ImmunoTech Inc. Releases Virtual Investor Segment Featuring Dr. Charles Lapp Discussing Ampligen® and ME/CFS Research
Barchart · 12/06 18:26
Kellner Group Urges AIM Stockholders To Vote For Its Nominees To AIM Board
NASDAQ · 12/06 14:25
Kellner Group urges AIM ImmunoTech shareholders to vote the Gold card
TipRanks · 12/06 13:53
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
Barchart · 12/06 08:15
ISS Recommends AIM ImmunoTech Shareholders Vote "FOR" Company Nominees Nancy K. Bryan And Dr. William M. Mitchell; ISS Finds That Activist Group's Plan Is "Limited" And Does Not Justify Control Of The Board
Benzinga · 12/05 14:11
More
Webull provides a variety of real-time AIM stock news. You can receive the latest news about Aim Immunotech through multiple platforms. This information may help you make smarter investment decisions.
About AIM
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.